Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
2021 · Nature Cancer · 529 citations
https://doi.org/10.1038/s43018-021-00232-6
M
Mathilde Cabart
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
80
Papers
1.1K
Citations
14
h-index
16
i10-index
Mathilde Cabart is an academic researcher from Institut Bergonié. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Cancer, Stress, Anesthesia, and Immune Response. The author has an h-index of 14, co-authored 68 publications.
ORCID: 0000-0003-3132-0069Papers by this author
worksProstate cancer and PARP inhibitors: progress and challenges
2021 · Journal of Hematology & Oncology · 149 citations
https://doi.org/10.1186/s13045-021-01061-x
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response
2024 · Cell Reports Medicine · 19 citations
https://doi.org/10.1016/j.xcrm.2024.101831
Supplementary Table S2 from TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25232281.v1
Supplementary Table S4 from TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25232275.v1
1375P Sequential ctDNA profiling in patients with advanced non-small cell lung cancer: An interim analysis of the COPE randomized study
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.08.1430
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat